Lola Reid, PhD

Lola Reid, PhD

Professor
UNC-Chapel Hill 

32-36 Glaxo Building
Campus Box 7038
Chapel Hill, NC 27599-7038
919-966-4535


Education and Training

BA --UNC at Chapel Hill ---1969. Undergraduate studies in biology and chemistry.

PhD —UNC at Chapel Hill---1974. Graduate studies in endocrinology and neuroendocrinology.

Postdoctoral Training

University of California in San Diego (UCSD), CA---training with Drs. Gordon Sato and John Holland in cell biology and virology (NIH postdoctoral fellowship)
Jackson Laboratories in Bar Harbor, Maine—training with Dr. Kenneth Paigen in genetics
Pasteur Institute in Paris, France---Training with Drs. Francoise Kelly and Francois Jacob in cell biology

Areas of Interest

We have been studying the core mechanisms that govern differentiation and tissue-specific gene expression of epithelia.  They comprise those dictated by the epithelial-mesenchymal cell-cell relationships and those defined by stem cell and maturational lineage biology. The epithelial-mesenchymal cell-cell relationships are driven by synergistic effects of soluble signals (autocrine, paracrine, endocrine) with the effects of the extracellular matrix, an insoluble complex of collagens, adhesion molecules, proteoglycans and factors bound to these matrix components.  Tissue-specific gene expression is mediated by matrix-hormone/growth factor synergistic effect.  Most of these influence posttranscriptional regulatory mechanisms (translation, mRNA stability, protein stability, etc.).  Transcriptional regulation is governed primarily by soluble signals in combination with proteoglycans and more specifically with those soluble signals in combination with defined epitopes of the proteoglycan’s glycosaminoglycan (GAG) chains.  The most potent of these GAG chains are forms of heparins with specific sulfation patterns.  

The epithelial-mesenchymal cell-cell mechanisms are subsumed by ones involving lineage-dependent phenotypic traits of stem cells and their maturational lineage descendants.  The maturation of the epithelia is coordinated with that of their mesenchymal cell partners. This results in lineage-dependent expression of paracrine signals, receptors and extracellular matrix components.

If recognition of these phenomena is utilized in strategies for handling cells, then these cells (of any tissue and from any species) can be maintained as stem cells or as one of the intermediates in the maturational cell lineages or as fully mature cells ex vivo in monolayer cultures, in organoid cultures (floating aggregates of the cells), or as bioartificial organs in perfusion bioreactors.  Optimization of the differentiation depends on using serum-free, wholly defined conditions of soluble signals and of extracellular matrix extracts or components. 

 These principals also form the foundation for strategies for cell therapies for dysfunctional tissues or organs. Transplantation of mature cells can confer some relief of dysfunctions, but with very transient effects.  Long-term effects (and even cure) of dysfunctions occurs with transplantation of stem cell organoids comprised of epithelial stem cells and their mesenchymal stem cell partners. 

Proof of these principals has been achieved in experimental studies in liver and pancreas in rodent, pig, and human model systems.  The experimental studies have led to successful, completed clinical trials of stem cell therapies for liver dysfunctions in humans in India and with approval for use throughout India.  Similar clinical trials are now ongoing in Europe.  Although these initial clinical trials have made use of transplantation of stem cells via a vascular route, we are now establishing grafting strategies for transplantation of stem cells into and onto internal organs.  The grafting strategies have proven successful in transplanting large numbers of cells into liver and pancreas and are now being tested for their efficacy in correcting hepatic or pancreatic dysfunctions.   

The findings and the technologies have been described in detail in publications and patents.  The patents have been licensed to biotechnology companies, particularly to Vesta Therapeutics (Bethesda, MD) for clinical uses and to PhoenixSongs Biologicals (Branford, CT) for uses for non-clinical commercial products.

Awards and Honors

Cutter Lab Scholarship

Scholarship to study in Germany for a year

Graduated from UNC with high honors

Teaching fellowship

NIH pre-doctoral and postdoctoral fellowship awards

Sinsheimer career development award

NIH Career Development Award

American Cancer Society (ACS) Executive Award

Advisor to NASA on biological studies in space

Carl Vestling Lectureship

UNC Inventor of the Year  

Associate editor at Hepatology

External advisory board member of the Institute of Translational Hepatology (Beijing 302 Hospital, Beijing, China)

Adhoc member of multiple NIH and ACS Study Sections

Affiliations

Member, Lineberger Cancer Center

Founder and chief scientific officer of Vesta Therapeutics (Bethesda, MD)

Founder and chief scientific officer of PhoenixSongs Biologicals (Branford, CT)

Advisor to industry (biotechnology companies and pharmaceutical companies)